ELAN parrainera la 9e Conférence internationale sur la maladie d'Alzheimer
( BW) Presse Economique / Santé / Médicale
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 17, 2004--Elan
Corporation(NYSE:ELN):
La société présentera les nouvelles données issues de son programme d'immunothérapie visant à traiter la maladie d'Alzheimer et hébergera un colloque réunissant les principaux chercheurs travaillant sur la maladie d'Alzheimer
A cette occasion, les principaux chercheurs échangeront de nouvelles informations et ressources sur l'étiologie, la pathologie et le traitement de la maladie d'Alzheimer
Business Editors/Health/Medical Writers
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 17, 2004--Elan
Corporation(NYSE:ELN):
Company to present new data from its Alzheimer's Immunotherapy Program
and host symposium featuring leading Alzheimer's disease researchers
Leading Researchers to Share Groundbreaking Information and Resources
on the Etiology, Pathology, and Treatment of Alzheimer's
Elan Pharmaceuticals, Inc. today announced that it is the premier
sponsor of The 9th International Conference on Alzheimer's Disease and
Related Disorders, presented by the Alzheimer's Association. New data
from Elan's Alzheimer's research and development programs will be
presented at the conference, and Elan will also host a symposium
featuring leading Alzheimer's researchers from throughout the field.
The conference will take place at the Pennsylvania Convention Center
in Philadelphia from July 17th through July 22nd.
"Alzheimer's disease currently affects more than 13 million people
worldwide and the number is expected to grow significantly in the
coming years. At Elan, our scientists are deeply committed to
advancing the understanding of Alzheimer's and ultimately finding an
effective treatment for this devastating disease," said Dr. Dale
Schenk, Elan's Chief Scientific Officer. "We are pleased to take a
leading role in the International Conference and to actively support
the open scientific exchange that is critical to identifying
fundamental improvements in the care and treatment of people with
Alzheimer's.
"There has been immense progress in Alzheimer research in the last
two decades," said Sheldon Goldberg, President and CEO of the
Alzheimer's Association, the organizers of the event. "The
International Conference is the primary platform for showcasing new
knowledge and new discoveries, and a forum for sharing information
across research areas. We are at a critical time now where preventing
Alzheimer's is an objective that we believe the research community can
achieve in the next decade. The newest treatment advances in
Alzheimer's disease and steps toward prevention will be on display in
Philadelphia."
Elan has been at the forefront of Alzheimer's disease research for
almost two decades, in particular in advancing the understanding of
the beta-amyloid peptide - A-beta - that is the main building block of
amyloid plaques, which are a hallmark of Alzheimer's disease
neuropathology. Elan is also conducting research on beta secretase
inhibitors and gamma secretase inhibitors. Both beta and gamma
secretase contribute to the formation of A-beta.
Elan, in collaboration with Wyeth, is researching a number of
novel immunotherapeutic approaches as potential treatments for
Alzheimer's disease. The Elan-Wyeth research involving beta-amyloid
and plaque will be the subject of a number of presentations at the
conference, including key new findings from a Phase II immunotherapy
clinical trial. While that compound is no longer in development, Elan
and Wyeth have initiated a Phase I trial studying a new monoclonal
antibody specifically designed and engineered to clear the neurotoxin
beta-amyloid peptide that accumulates in the brains of patients with
Alzheimer's disease.
At the conference, Elan will also present data on its research in
beta secretase inhibitors and gamma secretase inhibitors.
It is currently estimated that 4.5 million people in the United
States suffer from AD and more than 13 million worldwide. Given
anticipated increases in the population age of the United States and
other countries, it is expected that more than 37 million people
worldwide will be afflicted by the disease by 2025. Additionally, by
2010, Medicare costs for beneficiaries with Alzheimer's are expected
to increase by approximately 50 percent, to $50 billion, according to
the Alzheimer's Association.
About Elan
Elan Corporation, plc is a neuroscience-based biotechnology
company that is focused on discovering, developing, manufacturing and
marketing advanced therapies in neurology, autoimmune diseases, and
severe pain. Elan (NYSE: ELN) shares trade on the New York, London and
Dublin Stock Exchanges. For additional information about the company,
please visit http://www.elan.com.
CONTACT:
Elan Pharmaceuticals
Investors: Emer Reynolds
353-1-709-4000 or 800-252-3526
Media: Anita Kawatra
212-407-5755 or 800-252-3526
ESHEET: 4641849
© CompanynewsGroup